ClinicalTrials.gov
ClinicalTrials.gov Menu

Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02700386
Recruitment Status : Recruiting
First Posted : March 7, 2016
Last Update Posted : September 7, 2018
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The proposed study is being done to learn more about a particular dose of radiation treatment for breast cancer that is completed in a shorter amount of time than what has traditionally been used to treat breast cancer. Subjects are being asked to be in this research study because they have already had surgery for breast cancer and some cancer cells were found in their lymph nodes that drain the breast tissue.

Condition or disease Intervention/treatment Phase
Breast Cancer Combination Product: Adjuvant Hypofractionated Radiation Phase 2

Detailed Description:
Subjects who join the study will receive a shortened course of radiation treatment that will last approximately four (4) weeks, instead of the traditional six (6) week course that women have typically received in this situation. The shorter course subjects will receive is designed in a way that it is thought to be equivalent to the longer course. This shorter course has already been shown to be very safe and effective when treating breast cancer in the breast tissue only. However, because cancer cells were found in the lymph nodes that drain their breast, subjects require radiation to a larger area of their chest, armpit, and shoulder than has been completely tested with this experimental dose.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hypofractionated, Comprehensive Radiation Therapy for Node-Positive Breast Cancer
Actual Study Start Date : August 11, 2016
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Adjuvant Hypofractionated Radiation
Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a "boost" or "conedown") to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions.
Combination Product: Adjuvant Hypofractionated Radiation
Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
Other Name: Radiation Therapy




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03 [ Time Frame: Up to 60 months ]
    Any grade of 4 or 5 toxicity by CTCAE will qualify as a serious adverse event (SAE). Brachial plexopathy Grade 2 ('moderate symptoms; limiting instrumental activity of daily living (ADL)') or Grade 3 ('severe symptoms; limiting self-care ADL') and Grade 3 lymphedema ('Severe symptoms; limiting self-care ADL') and Grade 2 pneumonitis (requires steroids) will qualify as reportable adverse events (AE).

  2. Number of participants with lymphedema severity by measuring interlimb circumference [ Time Frame: Up to 60 Months ]
    An increase in interlimb arm circumference of at least 10% in the lower arm or the upper arm, or both, compared with the contralateral arm at the same timepoint, will be judged to be clinically significant lymphedema. Arm circumference 15 cm above the medial epicondyle (upper arms) and 15 cm below the medial epicondyle (lower arms) will be measured every 6 months, up to 60 months

  3. Number of participants with symptomatic rib fracture as measured by plain film or CT [ Time Frame: Up to 60 Months ]
    Symptomatic rib fracture will be diagnosed by evidence of a correlative lesion on plain film or CT.

  4. Number of participants with new development of ischemic heart disease as measured by EKG [ Time Frame: Up to 60 Months ]
    Ischemic heart disease will be measured by the new development of angina with corresponding EKG changes, or myocardial infraction.

  5. Number of participants reporting shoulder stiffness as measured by the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C3014) and breast-cancer module (BR23) [ Time Frame: Up to 60 Months ]
    Reported by the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C3014) and breast-cancer module (BR23).


Secondary Outcome Measures :
  1. Number of participants with disease recurrence [ Time Frame: Up to 60 months ]
    Recurrent disease presentation within axillary lymph node levels I, II, or III. The supraclavicular region is not included in this endpoint.

  2. Number of participants with metastasis-free survival [ Time Frame: Up to 60 months ]
    Measured by the time from date of enrollment to earlier of clinical detection of metastatic disease beyond the breast/chestwall and regional lymph nodes or death.

  3. Number of participants with local-regional failure free survival [ Time Frame: Up to 60 months ]
    Measured by the time from date of enrollment to earlier of clinical detection of any ipsilateral recurrent disease to the breast/chestwall or regional lymph nodes (levels I, II, III, supraclavicular, and internal mammary lymph nodes) or death.

  4. Number of participants with a change in quality of life score as measured by the EORTC QLQ-C3014 and breast-cancer module (BR23) [ Time Frame: Up to 60 months ]
    Patient's quality of life from pre-treatment to post-treatment, reported by the quality of life questionnaire [EORTC QLQ-C3014 and breast-cancer module (BR23)].



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 101 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult women (≥18 years old) with breast cancer who have undergone surgery for their primary breast tumor (either lumpectomy or mastectomy +/- reconstruction) and are confirmed to have involved lymph nodes on surgical pathology.
  2. Patient who have undergone either a total mastectomy or a lumpectomy are eligible. Acceptable procedures for assessment of axillary nodal status at the time of surgery include:

    • axillary node dissection;
    • sentinel node biopsy alone; or
    • sentinel node biopsy followed by axillary node dissection.
  3. Eligible women include (American Joint Committee on Cancer) AJCC 7th ed. Stage cN0 or cN1 subsequently staged after surgery as Stage pIB (N1mic), pIIA, pIIB, pIIIA, or pIIIB: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery. Note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollment.
  4. The patient must have recovered from surgery with the incision completely healed and no signs of infection. If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of radiation therapy should have resolved. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (KPS >70%).
  5. The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 180 days if chemotherapy is not delivered adjuvantly. If adjuvant chemotherapy was administered, the interval between the last chemotherapy treatment and randomization must be no more than 180 days.
  6. Before the patient is enrolled, the consent form, including any addenda, must be signed and dated by the patient and the person who explains the study to that patient.

Exclusion Criteria:

  1. patients <18 years old
  2. pregnant women
  3. male patients
  4. women with T4 disease, including inflammatory breast cancer
  5. women who have declined or otherwise not received preceding surgery
  6. women with positive margins after primary surgery
  7. women with node negative disease
  8. women without histologic confirmation of nodal involvement
  9. women more than 180 days out from primary breast surgery or adjuvant chemotherapy
  10. patients with clinically detected or suspicious lymph node involvement not readily amenable to surgical treatment (≥cN2 disease)
  11. patients with synchronous bilateral breast cancers
  12. patients with prior ipsilateral thoracic or breast radiation
  13. patients with distant metastatic disease (cM1) or a life expectancy of less than 5 years
  14. active collagen vascular disease, specifically dermatomyositis with a creatine phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma.
  15. other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
  16. patients with psychiatric or addictive disorders or other conditions that, in the opinion of the Investigator, would preclude the patient from meeting the study requirements.
  17. patients with a separate non-cutaneous cancer diagnosis for which the patient has not been without evidence of disease for at least 5 years

Note: women <50 years of age, women who received chemotherapy, pN0 (i+ or mol+), and large-breasted women are eligible for enrollment.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02700386


Contacts
Contact: Chelsea Schaefer chelsea.schaefer@ucdenver.edu

Locations
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Chrisitne Fisher, MD       christine.fisher@ucdenver.edu   
Principal Investigator: Christine Fisher, MD, MPH         
Sub-Investigator: Rachel Rabinovitch, MD         
Memorial Hospital Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Jane Ridings, MD    719-365-6800    jane.ridings@uchealth.org   
Sub-Investigator: Jane Ridings, MD         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Joshua Petit, MD    970-482-3328    joshua.petit@uchealth.org   
Sub-Investigator: Joshua Petit, MD         
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Principal Investigator: Christine Fisher, MD, MPH University of Colorado, Denver

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02700386     History of Changes
Other Study ID Numbers: 15-1329.cc
First Posted: March 7, 2016    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by University of Colorado, Denver:
Breast
Cancer
Hypofractionated
Node-Positive Breast Cancer
Radiation Therapy
Comprehensive Radiation Therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases